SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Scott Weiner will be moderating a panel, The Partnering Conundrum: To Partner or Not to Partner, That is the Question..., at the Bio 2011 conference in Washington, D.C.
News | 06. 28. 2011
